单疗法对牛皮指甲的相对影响:一个网络元分析研究
Aditya K Gupta1,2, Mary A Bamimore1, Tong Wang1
1Mediprobe Research Inc., London, Ontario, Canada.
Journal of cosmetic dermatology
|January 8, 2026
概括
托法西提尼布10毫克每天两次在改善指甲牛皮严重程度指数 (NAPSI) 评分方面显示出最高的疗效. 伊克西祖马布在实现清晰或几乎清晰的指甲方面表现出最佳结果,指导了指甲牛皮的治疗决策.
科学领域:
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 指甲牛皮 (NP) 是一个重大挑战,有各种治疗方案可供选择.
- 确定不同单一疗法的比较有效性对于优化患者护理至关重要.
研究的目的:
- 进行贝叶斯网络元分析 (NMA) 来比较不同单一治疗指甲牛皮的相对疗效.
- 根据指甲牛皮严重程度指数 (NAPSI) 和医生指甲全球评估 (PGA-f) 的变化来评估治疗方法.
主要方法:
- 系统的文献审查遵循PICO框架,以确定符合条件的研究.
- 贝叶斯网络元分析 (NMA) 用于估计相对治疗效应和SUCRA值.
- 对特定干预措施进行了比较疗效评估,包括deucravacitinib,risankizumab和golimumab.
主要成果:
- 托法西提尼布10毫克每天两次在16-24周的NAPSI平均变化 (SUCRA=99.71%) 中排名最高.
- "Ixekizumab在第0周服用160毫克,然后每4周服用80毫克"在获得PGA-f值为0或1 (SUCRA=95.67%) 的方面排名最高.
- 评估了22个活跃的比较器,为生物和非生物药物提供了比较数据.
结论:
- 这项研究提供了有关各种指甲牛皮单疗法的有效性有价值的比较证据.
- 这些发现可以为临床决策提供信息,以选择指甲牛皮的最佳治疗方法.
- 网络元分析为使用有限的直接比较数据进行治疗比较提供了强大的方法.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
01:27Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
146
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
146
01:30Combined Effects of Drugs: Antagonism
11.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.5K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
177
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
177
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248